- Bupa Platinum consultant
- Fee assured
- Verified account
- Open Referral network
Specialises in
- Haemato-oncology
Offers
- Face-to-face consultations
- Video and telephone consultations
About me
Dr Satyen Gohil is a recognised expert haematologist and specialises in treating patients with chronic lymphocytic leukaemia; all types of lymphoma; rarer haematological conditions such as Castleman's Disease and Histiocytic disorders (Langerhans Cell Histiocytosis, Rosai Dorfman Disease, Erdheim Chester Disease).
He provides national guidance and is commonly called to provide expert opinions on complex patients.
He is actively involved in clinical research and leads numerous clinical trials and is passionate about provided highly tailored treatment options for patients.
Areas of interest
Chronic Lymphocytic Leukaemia; CLL; Lymphoma; Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Burkitt's Lymphoma; Marginal Zone Lymphoma; T Cell Lymphoma; Langerhans Cell Histiocytosis; Erdheim Chester Disease; Rosai Dorfman Disease; Histiocytic Disorders; Autografts; Autologous Bone Marrow Transplant; CAR-T Cell Therapy; Chimeric Antigen Receptor T Cell; Blood Cancer; Anaemia; Thrombocytopaenia; Lymphadenopathy; Lymph Nodes; Second Opinion
Medical secretaries
- Amanda Borg-Cardona
- 5th Floor UCH Macmillan Cancer Centre Huntley Street London WC1E 6AG
- 020 3319 7164
- 020 3319 7164
- uclh.gohil.privatehcapa@nhs.net
Information for healthcare professionals (Bupa patients only, last 12 months)
-
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - ()
-
X0005
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-56 days - ()
-
X0003
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - ()
-
X0001
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 0-7 days - ()